UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
A randomized, double-blind, placebo-controlled study of ibrutinib, a
Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine
in the first-line treatment of patients with metastatic pancreatic
adenocarcinoma (RESOLVE).
Authors*: Margaret A. Tempero, Lisa M Coussens, Lawrence Fong, Robert Manges, Priyanka Singh,
Yunfeng Li, George W. Cole, Danelle Frances James, Josep Tabernero
Abstract #: TPS2601
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM
Location: Hall A, Poster Board #296a
Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS2601)
Tempero Research Interests: My research focuses on pancreatic ductal adenocarcinoma, especially in
investigational therapeutics. I was a pioneer in the use of mAb-based therapies and helped develop the fixed
dose rate concept for gemcitabine. My group developed effective gemcitabine combinations, provided a
foundation for using CA19-9 as a clinical surrogate for survival and currently is assessing molecular subtypes
and molecular enrichment for selecting new drugs for clinical evaluation. We have a strong emphasis on
immunotherapy. I am a SU2C Dream Team member evaluating innovative immunotherapy approaches in this
disease. I am also co-PI of a U01 award to establish high risk cohorts for testing candidate early diagnosis
biomarkers. I am the UCSF Pancreas Center Director and Pancreas Cancer Program Leader. I have served
as the NCCN Guidelines Panel Chair on Pancreatic Cancer since 2000. I serve on SABs to many groups and
institutions including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program.
http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701
*UCSF authors in bold
52